98%
921
2 minutes
20
Lung cancer is a devastating public health threat and a leading cause of cancer-related deaths. Therefore, it is imperative to develop sophisticated techniques for the non-invasive detection of lung cancer. Extracellular vesicles expressing programmed death ligand-1 (PD-L1) markers (PD-L1@EVs) in the blood are reported to be indicative of lung cancer and response to immunotherapy. Our approach is the development of a colorimetric aptasensor by combining the rapid capturing efficiency of (FeO)-SiO-TiO for EV isolation with PD-L1 aptamer-triggered enzyme-linked hybridization chain reaction (HCR) for signal amplification. The numerous HRPs catalyze their substrate dopamine (colorless) into polydopamine (blackish brown). Change in chromaticity directly correlates with the concentration of PD-L1@EVs in the sample. The colorimetric aptasensor was able to detect PD-L1@EVs at concentrations as low as 3.6×10 EVs/mL with a wide linear range from 10 to 10 EVs/mL with high specificity and successfully detected lung cancer patients' serum from healthy volunteers' serum. To transform the qualitative colorimetric approach into a quantitative operation, we developed an intelligent convolutional neural network (CNN)-powered quantitative analyzer for chromaticity in the form of a smartphone app named ExoP, thereby achieving the intelligent analysis of chromaticity with minimal user intervention or additional hardware attachments for the sensitive and specific quantification of PD-L1@EVs. This combined approach offers a simple, sensitive, and specific tool for lung cancer detection using PD-L1@EVs. The addition of a CNN-powered smartphone app further eliminates the need for specialized equipment, making the colorimetric aptasensor more accessible for low-resource settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798968 | PMC |
http://dx.doi.org/10.3389/fimmu.2024.1479403 | DOI Listing |
Multimed Man Cardiothorac Surg
September 2025
Department of Thoracic Surgery, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, UK
Three-dimensional (3D) guided robotic-assisted thoracic surgery is increasingly recognized as the pioneering approach for the most complex of pulmonary resections, offering high-definition 3D visualization, enhanced instrument augmentation and tremor-free tissue articulation. Compared with open thoracotomy, the robotic platform is associated with reduced peri-operative morbidity, shorter hospital admissions and faster patient recovery. However, sublobar resections such as segmentectomies remain anatomically and technically demanding, particularly in the context of resecting multiple segments, as showcased in this right S1 and S2 segmentectomy.
View Article and Find Full Text PDFMultimed Man Cardiothorac Surg
September 2025
Department of Cardiothoracic Surgery, St George’s Hospital, St George's University Hospitals NHS Foundation Trust, London, UK
Three-dimensional (3D) guided robotic-assisted thoracic surgery is increasingly recognized as a leading technique for undertaking the most complex pulmonary resections, providing high-definition 3D visualization, advanced instrument control and tremor-free tissue handling. Compared with open thoracotomy, the robotic platform offers reduced peri-operative complications, shorter hospital stays and faster patient recovery. Nevertheless, sublobar resections, such as segmentectomies, remain both anatomically intricate and technically challenging, particularly when resecting multiple segments, as in this left S1 and S2 segmentectomy.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFRadiol Med
September 2025
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.
View Article and Find Full Text PDFNeuroradiology
September 2025
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Purpose: To develop and validate an integrated model based on MR high-resolution vessel wall imaging (HR-VWI) radiomics and clinical features to preoperatively assess periprocedural complications (PC) risk in patients with intracranial atherosclerotic disease (ICAD) undergoing percutaneous transluminal angioplasty and stenting (PTAS).
Methods: This multicenter retrospective study enrolled 601 PTAS patients (PC+, n = 84; PC -, n = 517) from three centers. Patients were divided into training (n = 336), validation (n = 144), and test (n = 121) cohorts.